Standard

Biologically active compounds based on the privileged 2-imidazoline scaffold: the world beyond adrenergic/imidazoline receptor modulators. / Krasavin, M.

в: European Journal of Medicinal Chemistry, Том 97, 2015, стр. 525-537.

Результаты исследований: Научные публикации в периодических изданияхОбзорная статьяРецензирование

Harvard

APA

Vancouver

Author

BibTeX

@article{4470e0c7e9824289ad66ae7da467c51f,
title = "Biologically active compounds based on the privileged 2-imidazoline scaffold: the world beyond adrenergic/imidazoline receptor modulators",
abstract = "{\textcopyright} 2014 Elsevier Masson SAS. 2-Imidazolines are well known as pharmacophores for various isoforms of adrenergic (α) and imidazoline (I) receptors. The biological activities exerted through the modulation of these targets, mostly in the central nervous system, have found utility in the development of many drug candidates - and even marketed drugs - for hypertension, diabetes and various CNS disorders. However, there is a growing evidence for the general privileged character of the 2-imidazoline scaffold, considering the documented success in the development of numerous biologically active compounds acting outside of the α/I receptor domain. In this review, we provide an overview of these, less traditional areas of medicinal applications of 2-imidazolines.",
author = "M. Krasavin",
year = "2015",
doi = "10.1016/j.ejmech.2014.11.028",
language = "English",
volume = "97",
pages = "525--537",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Biologically active compounds based on the privileged 2-imidazoline scaffold: the world beyond adrenergic/imidazoline receptor modulators

AU - Krasavin, M.

PY - 2015

Y1 - 2015

N2 - © 2014 Elsevier Masson SAS. 2-Imidazolines are well known as pharmacophores for various isoforms of adrenergic (α) and imidazoline (I) receptors. The biological activities exerted through the modulation of these targets, mostly in the central nervous system, have found utility in the development of many drug candidates - and even marketed drugs - for hypertension, diabetes and various CNS disorders. However, there is a growing evidence for the general privileged character of the 2-imidazoline scaffold, considering the documented success in the development of numerous biologically active compounds acting outside of the α/I receptor domain. In this review, we provide an overview of these, less traditional areas of medicinal applications of 2-imidazolines.

AB - © 2014 Elsevier Masson SAS. 2-Imidazolines are well known as pharmacophores for various isoforms of adrenergic (α) and imidazoline (I) receptors. The biological activities exerted through the modulation of these targets, mostly in the central nervous system, have found utility in the development of many drug candidates - and even marketed drugs - for hypertension, diabetes and various CNS disorders. However, there is a growing evidence for the general privileged character of the 2-imidazoline scaffold, considering the documented success in the development of numerous biologically active compounds acting outside of the α/I receptor domain. In this review, we provide an overview of these, less traditional areas of medicinal applications of 2-imidazolines.

U2 - 10.1016/j.ejmech.2014.11.028

DO - 10.1016/j.ejmech.2014.11.028

M3 - Review article

VL - 97

SP - 525

EP - 537

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -

ID: 3924633